

SANOFI-AVENTIS
Form 6-K
May 11, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

□□□□□□□□

**FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

□□□□□□□□

For the month of May 2006

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F
x o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____

Exhibit List

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated May 11, 2006: Study published in <i>The Lancet</i> about sanofi pasteur H5N1 pandemic influenza vaccine candidate

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 11, 2006

SANOFI-AVENTIS

By: /s/ Patricia Kodyra

Name: Patricia Kodyra

Title: Associate Vice President
Financial and Securities Law

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release dated May 11, 2006: Study published in <i>The Lancet</i> about sanofi pasteur H5N1 pandemic influenza vaccine candidate